Toku adds Dr. Robert Weinreb to its Board of Directors

– USA, CA –  Toku, Inc. announced the appointment of Dr. Robert N. Weinreb (MD) to its Board of Directors.

About Dr. Robert N. Weinreb

Dr. Weinreb’s distinguished career encompasses groundbreaking research and clinical practice. As the Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego, and Director of the Shiley Eye Institute and the Hamilton Glaucoma Center. This week it was announced that Dr Weinreb joined the Ophthalmologist Power List Hall of Fame. He brings unparalleled expertise to the Toku board.

About Toku, Inc.

Toku, Inc. is a cutting-edge technology company specializing in developing non-invasive, AI-powered diagnostic and screening tools using retinal imaging to measure cardiovascular and other health risk factors. The company’s first commercialized product, BioAge, analyzes biometric markers visible in the retinal image to measure an individual’s biological age accurately. The test can provide a detailed report on an individual’s overall health. The Company is also developing the CLAiR platform, an AI-powered technology to assess cardiovascular risk using retinal photographs of the back of the eye. The CLAiR platform received Breakthrough Device designation from the FDA in November 2023 and CE & UKCA Marks in 2024. MyKidneyAI is the latest in Toku’s suite of products. Toku is committed to making its technology widely accessible through its major partnerships worldwide. The company’s technology is built on the latest research in AI, and its team of experts includes leading scientists and medical professionals.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.